Berdazimer: Insights On The First FDA-Approved Molluscum Gel
First-in-class nitric oxide-releasing gel for molluscum contagiosum treatment and acne evaluation.
Berdazimer is a pioneering nitric oxide (NO)-releasing topical gel designed primarily for treating molluscum contagiosum (MC), a common viral skin infection, and is currently under investigation for acne vulgaris.
What is berdazimer?
Berdazimer, marketed as Zelsuvmi (10.3% gel), represents the first FDA-approved topical therapy specifically for molluscum contagiosum, granted approval in 2024 for patients aged 6 months and older. This first-in-class medication addresses a significant gap in treatments for MC, which affects millions worldwide, particularly children, causing pearly, umbilicated papules that spread through skin contact or fomites. Unlike traditional options like cryotherapy or curettage, berdazimer offers at-home application with targeted NO release, minimizing pain and clinic visits.
MC is caused by molluscum contagiosum virus (MCV), a poxvirus that evades immune clearance, leading to persistent lesions lasting 6-12 months or longer. Berdazimer 3.4% gel is in Phase III trials for acne, highlighting its potential broader dermatological applications.
Mechanism of action
Berdazimer leverages nitric oxide, a naturally occurring molecule produced by the human body with antimicrobial, immunomodulatory, and antiviral properties. NO functions through protein nitrosylation, influencing immunomodulation, apoptosis, cytokine production, and inflammation reduction while generating cytotoxic reactive oxygen and nitrogen species that inhibit viral replication.
The gel comprises berdazimer sodium—a novel chemical entity with a diazeniumdiolate silicon backbone covalently bound to NO donors—and a proton-donating hydrogel. Upon coapplication, these components trigger stable, site-specific NO release directly into affected skin, avoiding systemic absorption. This targeted delivery disrupts MCV DNA synthesis, assembly, and propagation, while enhancing host immune responses via NF-κB modulation.
In preclinical models, NO from berdazimer demonstrated potent antiviral effects against MCV, promoting lesion resolution without widespread tissue damage.
Pharmacokinetics
Berdazimer exhibits minimal systemic exposure due to its localized NO release mechanism. Pharmacokinetic studies in MC patients applying 10.3% gel once daily showed negligible plasma concentrations of berdazimer or its metabolites, confirming skin-targeted action. This profile supports safe use across age groups, including pediatrics, with no accumulation over 12 weeks.
Application
For MC, a thin layer of berdazimer 10.3% gel is applied once daily to all treatable lesions (up to 70) for up to 12 weeks. Patients or caregivers use the applicator to dab gel precisely on lesions, allowing it to dry before covering. Treatment continues until clearance or maximum duration, with non-responders evaluated for alternatives.
- Apply to clean, dry skin.
- Avoid eyes, mouth, mucous membranes.
- Wash hands post-application.
- Do not cover unless directed.
Contraindications
Hypersensitivity to berdazimer or excipients is the primary contraindication. No other specific contraindications are noted, but caution is advised in open wounds or severe dermatitis. Safe for atopic dermatitis patients per subgroup analyses.
Benefits
Berdazimer offers key advantages over invasive MC therapies:
- Non-invasive self-treatment: Home application reduces pain, scarring, and procedural anxiety, ideal for children.
- High efficacy: In B-SIMPLE4 Phase III trial (n=891, ages ≥6 months), 32.4% achieved complete lesion clearance at week 12 vs. 19.7% vehicle (OR 2.0, P<0.001).
- Broad applicability: Effective across lesion counts (3-70), ages, and comorbidities like atopic dermatitis.
- Immunomodulation: Boosts clearance while minimizing recurrence risk.
- Acne potential: Phase III trials ongoing for inflammatory acne.
Meta-analyses of four RCTs (n=1854) confirm superior lesion clearance and scarring reduction.
Disadvantages
While effective, limitations include:
- Daily application for up to 12 weeks may affect adherence.
- Not 100% clearance rate (32-40% in trials).
- Potential local irritation in sensitive skin.
- Cost and access as prescription gel.
- Limited long-term data beyond 12 weeks.
Side effects and risks
Berdazimer is well-tolerated, with mostly mild, transient local skin reactions (LSRs). In B-SIMPLE trials (n=1598), common AEs:
| Adverse Event | Berdazimer (%) | Vehicle (%) |
|---|---|---|
| Erythema | 20.4 | 14.2 |
| Application site pain | 11.8 | 6.5 |
| Dryness | 9.2 | 5.1 |
| Pruritus | 8.7 | 6.3 |
| Skin vesicle | 3.5 | 1.2 |
LSR scores peaked weeks 2-4 then declined; <2% discontinued due to AEs. No serious systemic events; safe in pediatrics and AD patients. Risks include contact dermatitis if overused; monitor for hypersensitivity.
Clinical trials
Pivotal B-SIMPLE program (three Phase III RCTs, n=1598) established efficacy.
- B-SIMPLE4: 891 patients; 32.4% complete clearance vs. 19.7% vehicle at week 12; 75% ≥90% lesion reduction.
- Secondary endpoints: Faster clearance at week 8, sustained reductions.
- Subgroups: Consistent efficacy in children, AD patients.
Meta-analysis (four RCTs) showed significant odds for clearance (OR 1.8-2.2). PK studies confirmed safety.
Investigational use
Berdazimer 3.4% gel advances in Phase III for acne, targeting inflammation via NO’s antimicrobial effects.
Frequently Asked Questions
Who can use berdazimer?
Aged ≥6 months with confirmed MC lesions; consult dermatologist.
How long until results?
Clearance by week 12; reductions from week 4.
Is it safe for children?
Yes, largest pediatric MC trial cohort; mild local effects.
Does it prevent spread?
Reduces viral load; combine with hygiene.
What if no improvement?
Discontinue after 12 weeks; seek alternatives.
References
- Berdazimer – DermNet — DermNet NZ. 2024. https://dermnetnz.org/topics/berdazimer
- Zelsuvmi for Molluscum Contagiosum: Clinical Evidence — PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12767985/
- Safety and efficacy of topical nitric oxide‐releasing berdazimer gel — Wiley Online Library. 2023-09-18. https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.15419
- Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel — Journal of Drugs in Dermatology. 2022. https://jddonline.com/articles/pharmacokinetic-profile-safety-and-tolerability-of-topical-berdazimer-gel-103-in-patients-with-molluscum-contagiosum-S1545961622P1104X/
- Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer — JAMA Dermatology. 2022. https://jamanetwork.com/journals/jamadermatology/fullarticle/2794188
Similar Articles
Read full bio of Sneha Tete
